Skip to main content
SpringerLink
Log in

Author’s Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Rasool MF, Khalil F, Laer S. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet. 2015;54(9):943–62.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Li GF, Gu X, Yu G, Zhao SY, Zheng QS. Comment on:"A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows". Clin Pharmacokinet. 2015;54(9):943–62.

    Article  Google Scholar 

  3. Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014;64(11):1092–102.

    Article  PubMed  Google Scholar 

  4. Muller AF, Batin P, Evans S, Hawkins M, Cowley AJ. Regional blood flow in chronic heart failure: the reason for the lack of correlation between patients’ exercise tolerance and cardiac output? Br Heart J. 1992;67(6):478–81.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Maharaj A, Edginton A, Fotaki N. Assessment of age-related changes in pediatric gastrointestinal solubility. Pharm Res. 2015. doi:10.1007/s11095-015-1762-7

    PubMed  Google Scholar 

  6. Carlton LD, Pollack GM, Brouwer KL. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol. J Pharm Sci. 1996;85(5):473–7.

    Article  PubMed  CAS  Google Scholar 

  7. Tenero D, Boike S, Boyle D, Ilson B, Fesniak HF, Brozena S, et al. Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol. 2000;40(8):844–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine University, 40225, Düsseldorf, Germany

      Muhammad Fawad Rasool, Feras Khalil & Stephanie Läer

    2. Faculty of Pharmacy, Bahauddin Zakariya University, Multan, 60800, Pakistan

      Muhammad Fawad Rasool

    Authors
    1. Muhammad Fawad Rasool
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Feras Khalil
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Stephanie Läer
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Muhammad Fawad Rasool.

    Ethics declarations

    Conflicts of interest

    M. Fawad Rasool, Feras Khalil and Stephanie Laër have no conflicts of interest that might be relevant to the contents of this manuscript.

    Additional information

    M. F. Rasool and F. Khalil contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Rasool, M.F., Khalil, F. & Läer, S. Author’s Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clin Pharmacokinet 55, 139–141 (2016). https://doi.org/10.1007/s40262-015-0349-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40262-015-0349-0

    Keywords

    Search

    Navigation